Giant cell arteritis

Jonathan H. Smith, Jerry W. Swanson

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Giant cell arteritis (GCA) is a medium and large-vessel vasculitis, which is an important cause of secondary headache in older adults. While GCA has a classic presentation occurring after the age of 50, atypical presentations (eg, fever of unknown origin, cough, low or normal erythrocyte sedimentation rate) may lead to a delay in diagnosis. The topography of vascular involvement has implications for disease-related complications, which can result in neurologic disease at multiple levels of the nervous system. The most feared complication, vision loss, fortunately becomes uncommon after initiation of corticosteroids. Corticosteroid treatment should not be withheld while waiting the results of a temporal artery biopsy (TAB), which remains the gold standard for GCA diagnosis. Newer diagnostic modalities, including ultrasound, magnetic resonance imaging, and positron emission tomography can play an important role in directing treatment in cases with negative TAB. After successful control of the disorder, patients should be gradually tapered off corticosteroids, with careful monitoring using both clinical and laboratory parameters to assess for relapse. Corticosteroid-related treatment complications are not uncommon in GCA. There is mixed evidence for use of adjunct corticosteroid-sparing agents (eg, methotrexate), although these should be initiated in the setting of corticosteroid-related morbidity and/or cases with frequent relapse.

Original languageEnglish (US)
Pages (from-to)1273-1289
Number of pages17
JournalHeadache
Volume54
Issue number8
DOIs
StatePublished - Sep 1 2014

Fingerprint

Giant Cell Arteritis
Adrenal Cortex Hormones
Temporal Arteries
Fever of Unknown Origin
Biopsy
Recurrence
Blood Sedimentation
Vasculitis
Nervous System Diseases
Cough
Methotrexate
Positron-Emission Tomography
Nervous System
Blood Vessels
Headache
Therapeutics
Magnetic Resonance Imaging
Morbidity

Keywords

  • cranial arteritis
  • elderly
  • giant cell arteritis
  • older adult
  • secondary headache
  • temporal arteritis

ASJC Scopus subject areas

  • Clinical Neurology
  • Neurology
  • Medicine(all)

Cite this

Smith, J. H., & Swanson, J. W. (2014). Giant cell arteritis. Headache, 54(8), 1273-1289. https://doi.org/10.1111/head.12425

Giant cell arteritis. / Smith, Jonathan H.; Swanson, Jerry W.

In: Headache, Vol. 54, No. 8, 01.09.2014, p. 1273-1289.

Research output: Contribution to journalArticle

Smith, JH & Swanson, JW 2014, 'Giant cell arteritis', Headache, vol. 54, no. 8, pp. 1273-1289. https://doi.org/10.1111/head.12425
Smith JH, Swanson JW. Giant cell arteritis. Headache. 2014 Sep 1;54(8):1273-1289. https://doi.org/10.1111/head.12425
Smith, Jonathan H. ; Swanson, Jerry W. / Giant cell arteritis. In: Headache. 2014 ; Vol. 54, No. 8. pp. 1273-1289.
@article{1b5b73815f084ff0a9cf6af7aa3db5a8,
title = "Giant cell arteritis",
abstract = "Giant cell arteritis (GCA) is a medium and large-vessel vasculitis, which is an important cause of secondary headache in older adults. While GCA has a classic presentation occurring after the age of 50, atypical presentations (eg, fever of unknown origin, cough, low or normal erythrocyte sedimentation rate) may lead to a delay in diagnosis. The topography of vascular involvement has implications for disease-related complications, which can result in neurologic disease at multiple levels of the nervous system. The most feared complication, vision loss, fortunately becomes uncommon after initiation of corticosteroids. Corticosteroid treatment should not be withheld while waiting the results of a temporal artery biopsy (TAB), which remains the gold standard for GCA diagnosis. Newer diagnostic modalities, including ultrasound, magnetic resonance imaging, and positron emission tomography can play an important role in directing treatment in cases with negative TAB. After successful control of the disorder, patients should be gradually tapered off corticosteroids, with careful monitoring using both clinical and laboratory parameters to assess for relapse. Corticosteroid-related treatment complications are not uncommon in GCA. There is mixed evidence for use of adjunct corticosteroid-sparing agents (eg, methotrexate), although these should be initiated in the setting of corticosteroid-related morbidity and/or cases with frequent relapse.",
keywords = "cranial arteritis, elderly, giant cell arteritis, older adult, secondary headache, temporal arteritis",
author = "Smith, {Jonathan H.} and Swanson, {Jerry W.}",
year = "2014",
month = "9",
day = "1",
doi = "10.1111/head.12425",
language = "English (US)",
volume = "54",
pages = "1273--1289",
journal = "Headache",
issn = "0017-8748",
publisher = "Wiley-Blackwell",
number = "8",

}

TY - JOUR

T1 - Giant cell arteritis

AU - Smith, Jonathan H.

AU - Swanson, Jerry W.

PY - 2014/9/1

Y1 - 2014/9/1

N2 - Giant cell arteritis (GCA) is a medium and large-vessel vasculitis, which is an important cause of secondary headache in older adults. While GCA has a classic presentation occurring after the age of 50, atypical presentations (eg, fever of unknown origin, cough, low or normal erythrocyte sedimentation rate) may lead to a delay in diagnosis. The topography of vascular involvement has implications for disease-related complications, which can result in neurologic disease at multiple levels of the nervous system. The most feared complication, vision loss, fortunately becomes uncommon after initiation of corticosteroids. Corticosteroid treatment should not be withheld while waiting the results of a temporal artery biopsy (TAB), which remains the gold standard for GCA diagnosis. Newer diagnostic modalities, including ultrasound, magnetic resonance imaging, and positron emission tomography can play an important role in directing treatment in cases with negative TAB. After successful control of the disorder, patients should be gradually tapered off corticosteroids, with careful monitoring using both clinical and laboratory parameters to assess for relapse. Corticosteroid-related treatment complications are not uncommon in GCA. There is mixed evidence for use of adjunct corticosteroid-sparing agents (eg, methotrexate), although these should be initiated in the setting of corticosteroid-related morbidity and/or cases with frequent relapse.

AB - Giant cell arteritis (GCA) is a medium and large-vessel vasculitis, which is an important cause of secondary headache in older adults. While GCA has a classic presentation occurring after the age of 50, atypical presentations (eg, fever of unknown origin, cough, low or normal erythrocyte sedimentation rate) may lead to a delay in diagnosis. The topography of vascular involvement has implications for disease-related complications, which can result in neurologic disease at multiple levels of the nervous system. The most feared complication, vision loss, fortunately becomes uncommon after initiation of corticosteroids. Corticosteroid treatment should not be withheld while waiting the results of a temporal artery biopsy (TAB), which remains the gold standard for GCA diagnosis. Newer diagnostic modalities, including ultrasound, magnetic resonance imaging, and positron emission tomography can play an important role in directing treatment in cases with negative TAB. After successful control of the disorder, patients should be gradually tapered off corticosteroids, with careful monitoring using both clinical and laboratory parameters to assess for relapse. Corticosteroid-related treatment complications are not uncommon in GCA. There is mixed evidence for use of adjunct corticosteroid-sparing agents (eg, methotrexate), although these should be initiated in the setting of corticosteroid-related morbidity and/or cases with frequent relapse.

KW - cranial arteritis

KW - elderly

KW - giant cell arteritis

KW - older adult

KW - secondary headache

KW - temporal arteritis

UR - http://www.scopus.com/inward/record.url?scp=84908263445&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84908263445&partnerID=8YFLogxK

U2 - 10.1111/head.12425

DO - 10.1111/head.12425

M3 - Article

C2 - 25041449

AN - SCOPUS:84908263445

VL - 54

SP - 1273

EP - 1289

JO - Headache

JF - Headache

SN - 0017-8748

IS - 8

ER -